February 2026 Options Now Available For Moderna (MRNA)

An analysis of Moderna (MRNA) options highlights two strategies for investors, with the stock currently trading at $25.94. A cash-secured put at the $21.00 strike offers a potential 17.56% annualized return if it expires worthless (76% probability), effectively targeting a $20.00 entry price. Conversely, a covered call at the $27.00 strike could yield 12.57% by February 2026 if shares are called away, or an annualized 31.27% premium if it expires worthless (45% probability). This options-based income generation and discounted entry analysis is set against MRNA's implied volatilities of 90% (put) and 77% (call), compared to its 68% historical volatility.

Analysis

Moderna (MRNA), currently trading at $25.94, is presented as a candidate for two distinct options strategies aimed at either generating income or achieving a discounted entry. These strategies leverage out-of-the-money put and call contracts, offering specific risk-reward profiles for investors.

A cash-secured put strategy at the $21.00 strike price, with a $1.00 bid, offers a potential entry point at an effective cost basis of $20.00, representing a 19% discount to the current share price. With a 76% probability of expiring worthless, this contract could yield a 17.56% annualized return on the cash commitment if not assigned.

Conversely, for existing MRNA shareholders, a covered call at the $27.00 strike, with a $2.20 bid, presents an opportunity to generate income. This strategy could yield a 12.57% total return by February 2026 if shares are called away, or an annualized 31.27% premium if the option expires worthless, which has a 45% probability.

The options' implied volatilities of 90% for the put and 77% for the call significantly exceed MRNA's trailing twelve-month historical volatility of 68%. This higher implied volatility suggests that option premiums are currently elevated relative to recent historical price movements, potentially benefiting option sellers.

Key Decisions for Investors

• Consider utilizing the cash-secured put strategy at the $21.00 strike for MRNA if seeking a discounted entry point, acknowledging the 76% probability of premium retention and 17.56% annualized return if the option expires worthless
• For current MRNA shareholders, evaluate the covered call strategy at the $27.00 strike to enhance portfolio yield, weighing the 12.57% potential return if shares are called away against the 31.27% annualized premium if the option expires worthless
• Pay close attention to MRNA's implied volatilities (90% for put, 77% for call) relative to its historical volatility (68%), as elevated implied volatility may present attractive selling opportunities for option premiums